ArticleNPJ precision oncology2026
IMIREG: a lineage-resolved regulon signature unveiling immune engagement archetypes and predicting immunotherapy response across diverse cancers.
Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Peripheral blood biomarkers in PD-1/PD-L1 immunotherapy: distinguishing predictive from prognostic biomarkers.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A critical barrier to maximizing immune checkpoint blockade (ICB) efficacy is the lack of biomarkers that capture the core regulatory dynamics of the tumor microenvironment. We developed IMIREG, a 14-regulon transcriptional signature derived from inferred transcription factor activity that quantifies immune engagement. Validated across 50 immunotherapy cohorts (52 treatment arms) spanning 16 cancer types, IMIREG robustly predicts clinical benefit (mean AUROC = 0.71), consistently outperforming established response and resistance signatures, including the T cell-inflamed, IFN-γ, CD8 T effector, and antigen presentation signatures. Crucially, its predictive utility is specific to the immunotherapy context rather than general prognosis. Single-cell analysis of 21 datasets revealed selective IMIREG enrichment in checkpoint-restrained exhausted/memory/effector T cells and pro-inflammatory M1 macrophages, defining an "immune-engaged but restrained" state primed for therapeutic reactivation. Our lineage-resolved framework classifies IMIREG-high tumors into T cell-, macrophage-, and dual-driven archetypes, revealing that the dual-driven phenotype is markedly diminished in metastatic compared to primary tumors. In triple-negative breast cancer, longitudinal single-cell analysis of neoadjuvant anti-PD-1/radiotherapy biopsies establishes IMIREG as a dynamic pharmacodynamic marker that discriminates spatial response trajectories, and predicts pathological complete response in on-treatment biopsies collected prior to radiation initiation. Together, IMIREG provides a mechanism-based biomarker that captures anti-tumor immune regulatory circuitry, improving ICB patient stratification and illuminating immune dynamics in cancer progression.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.